Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor-Reference-Cited by-同舟云学术

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor

Published:2016-12 Issue:12 Volume:28 Page:683-695
ISSN:2327-6924
Container-title:Journal of the American Association of Nurse Practitioners
language:en
Short-container-title:

Author:

Young Melodie,Roebuck Heather L.

Funder

Celgene

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Nursing

Reference31 articles.

1. Providing guidance for patients with moderate‐to‐severe psoriasis who are candidates for biologic therapy: Role of the nurse practitioner and physician assistant;Aldredge;Journal of Dermatology Nurses' Association,2016

2. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine;Alwan;Clinical and Experimental Rheumatology,2015

3. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: Findings from the National Psoriasis Foundation surveys, 2003–2011;Armstrong;JAMA Dermatology,2013

4. Maximizing patient adherence for optimal outcomes in psoriasis;Bewley;Journal of the European Academy of Dermatology and Venereology,2011

5. Patient‐relevant treatment goals in psoriasis;Blome;Archives of Dermatological Research,2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential;Cellular and Molecular Neurobiology;2023-04-19

2. The Undeniable Benefits of Apremilast in Psoriatic Arthritis: An Observational Study from South India;Advances in Pharmacology and Pharmacy;2022-07

3. An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India;Psoriasis: Targets and Therapy;2022-04

4. Development of an amorphous based sustained release system for apremilast a selective phosphodiesterase 4 (PDE4) inhibitor;International Journal of Pharmaceutics;2022-03

5. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data;Journal of the American Academy of Dermatology;2021-09